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Background: While most pediatric sarcomas respond to front-line therapy, some bone sarcomas do not show
radiographic response like soft-tissue sarcomas (rhabdomyosarccomas) but do show 90% necrosis. Though, new
therapies are urgently needed to improve survival and quality of life in pediatric patients with sarcomas. Complex
chromosomal aberrations such as amplifications and deletions of DNA sequences are frequently observed in pediatric
sarcomas. Evaluation of copy number variations (CNVs) associated with pediatric sarcoma patients at the time of diagnosis
or following therapy offers an opportunity to assess dysregulated molecular targets and signaling pathways that may
drive sarcoma development, progression, or relapse. The objective of this study was to utilize publicly available data sets
to identify potential predictive biomarkers of chemotherapeutic response in pediatric Osteosarcoma (OS),
Rhabdomyosarcoma (RMS) and Ewing’s Sarcoma Family of Tumors (ESFTs) based on CNVs following chemotherapy
(OS n = 117, RMS n = 64, ESFTs n = 25 tumor biopsies).
Methods: There were 206 CNV profiles derived from pediatric sarcoma biopsies collected from the public databases
TARGET and NCBI-Gene Expression Omnibus (GEO). Through our comparative genomic analyses of OS, RMS, and ESFTs
and 22,255 healthy individuals called from the Database of Genomic Variants (DGV), we identified CNVs (amplifications
and deletions) pattern of genomic instability in these pediatric sarcomas. By integrating CNVs of Cancer Cell Line
Encyclopedia (CCLE) identified in the pool of genes with drug-response data from sarcoma cell lines (n = 27) from Cancer
Therapeutics Response Portal (CTRP) Version 2, potential predictive biomarkers of therapeutic response were identified.
(Continued on next page)* Correspondence: Lang.Li@osumc.edu; kpollok@iu.edu; jarenbar@iu.edu
†Lijun Cheng and Pankita H. Pandya contributed equally to this work.
1Department of Biomedical Informatics, College of Medicine, Ohio State
University, Columbus, OH 43210, USA
2Herman B Wells Center for Pediatric Research, Department of Pediatrics,
School of Medicine, Indiana University, Indianapolis, IN 46202, USA
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Cheng et al. BMC Medical Genomics 2019, 12(Suppl 1):23 Page 90 of 189(Continued from previous page)
Results: Genes associated with survival and/recurrence of these sarcomas with statistical significance were found on long
arm of chromosome 8 and smaller aberrations were also identified at chromosomes 1q, 12q and x in OS, RMS, and ESFTs.
A pool of 63 genes that harbored amplifications and/or deletions were frequently associated with recurrence across OS,
RMS, and ESFTs. Correlation analysis of CNVs from CCLE with drug-response data of CTRP in 27 sarcoma cell lines, 33
CNVs out of 63 genes correlated with either sensitivity or resistance to 17 chemotherapies from which actionable CNV
signatures such as IGF1R, MYC, MAPK1, ATF1, and MDM2 were identified. These CNV signatures could potentially be used
to delineate patient populations that will respond versus those that will not respond to a particular chemotherapy.
Conclusions: The large-scale analyses of CNV-drug screening provides a platform to evaluate genetic alterations across
aggressive pediatric sarcomas. Additionally, this study provides novel insights into the potential utilization of CNVs as not
only prognostic but also as predictive biomarkers of therapeutic response. Information obtained in this study may help
guide and prioritize patient-specific therapeutic options in pediatric bone and soft-tissue sarcomas.
Keywords: Copy number variation, Pediatric sarcomas, Precision medicine, Prognostic biomarkers, Comparative genomic
hybridization-arrayBackground
Sarcomas are a rare form of soft-tissue and/or bone
cancers [1]. Osteosarcoma (OS), Rhabdomyosarcoma
(RMS) and Ewing sarcoma family of tumors (ESFTs) are
the three most common types of sarcomas that affect
mostly children and teenagers, and account for approxi-
mately 15% of all childhood malignancies in the United
States [2–6]. Only 30% of relapsed/recurrent OS, RMS
and ESFTs patients benefit from neoadjuvant chemother-
apy [7–9]. Thus, it is imperative to identify predictive bio-
markers of chemotherapeutic response in these pediatric
sarcoma patients to improve prognosis and clinical out-
comes. This will ultimately help to stratify patient popula-
tions that will respond to chemotherapy based on their
molecular landscape.
Genetic variation is one of many characteristics of
pediatric sarcomas [10–13]. It has been reported that DNA
copy number variations (CNVs) and gene fusions lead to
altered gene expression and eventually contribute to the
development of sarcoma [10–13]. There are 55 DNA struc-
ture variation sets listed as standard clinical diagnostic
biomarkers for sarcoma by the medical leader report of
National Comprehensive Cancer Network (NCCN) Bio-
markers Compendium [https://www.nccn.org/professionals/
biomarkers/default.aspx]. Forty-five out of 55 are fusion
gene variations, while 3 of the 55 genetic alterations are
CNVs. However, none of these alterations have been ap-
proved as predictive biomarkers for first line chemotherapy
treatment in pediatric sarcomas [https://www.nccn.org/pro
fessionals/biomarkers/default.aspx] (Additional file 1). Many
of these chromosomal changes may be responsible for
pediatric sarcoma progression and relapse, but the under-
lying cause of the large number of copy number amplifica-
tions and deletions remains unclear. Genetic alterations that
serve as prognostic biomarkers for aggressive pediatric sar-
comas will be investigated to also determine if they can be
used as predictive biomarkers of therapeutic response.OS is the most common primary malignant bone tumor
in children and adolescents and is characterized by com-
plex deregulated signaling [5, 7]. Comprehensive molecu-
lar profiling of OS shows copy number amplification and
overexpression of genes in chr8 and chr17p11.2-p12 that
strongly correlate with OS progression and relapse [5, 7].
Amplification of MET, CCNE1, and PDGFRα genes pro-
vides promising prognostic biomarkers for tailoring per-
sonalized therapies for OS patients [14]. Notably, ESFT is
the second most common primary malignant bone tumor
in children and adolescents. The most frequent copy
number gains are observed in whole chr 8 and chr 12,
long arm of chr 1. Copy number loss is commonly ob-
served on the long arm (q) of chr 16 correlates with
shorter survival in ESFTs [15, 16]. RMS is the most com-
mon soft tissue sarcoma in children. The frequent gains
and amplifications associated with short-term survival
include 12q13.3-q14.1 and 8p11.1–11.2 which harbor
CDK4, MYCN, GLI, MDM2, FGFR1, and FGFR4 genes
[17, 18]. Most of these biomarkers have been proposed for
a specific sarcoma subtypes (OS, ESFTs, RMS) but not for
all three pediatric sarcomas. These prognostic biomarkers
still need to be evaluated via genome-wide studies for
their role as potential predictive biomarkers of therapeutic
responses across multiple pediatric sarcoma subtypes.
There is still a critical need for elucidating predictive
biomarkers of therapeutic response for progressive pediatric
sarcomas. To this end, prognostic biomarkers of pediatric
sarcomas have the potential to also serve as predictive bio-
markers of therapeutic responses, which would help guide
and prioritize patient-specific therapeutic options. As men-
tioned above, chromosomal aberrations such as DNA copy
number amplifications and deletions are frequently ob-
served in pediatric sarcomas and can be retrospectively in-
tegrated with drug response data to ultimately allow for
predictions of response to chemotherapies. For our study,
we focused our efforts on exploiting high-resolution array
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distinguish such pediatric sarcoma-associated CNVs pat-
tern in OS, RMS, and ESFTs. This included comparison of
chromosome bands and genes in pediatric sarcomas to,
healthy population CNVs in the Database of Genomic
Variants (DGV) [20]. Comprehensive literature reviews
were also conducted to collect CNV amplifications and
deletions of many genes from the PubMed repository
which may serve as a tool for predicting clinical out-
comes in all three types of sarcomas.
Genomic variations can contribute to differences in can-
cer cell drug responses. Systematic cell line-based platforms
provide an important resource to evaluate the therapeutic
efficacy of candidate anticancer agents for sarcomas harbor-
ing similar genetic alterations such as chromosomal CNVs.
In the present study, we conducted a comprehensive CNV
profile comparison between sarcoma cell lines and patient
tumors. CNVs in 63 genes that serve as prognostic bio-
markers of pediatric sarcomas were evaluated to determine
if they correlated with sensitivity or resistance to a broad
class of DNA damaging chemotherapeutic agents using
Cancer Cell Line Encyclopedia (CCLE) [21] and The
Cancer Therapeutics Response Portal (CTRP) Version
2 [22]. The correlation of genetic alterations such as
CNVs and response to standard-of-care agents offers
the opportunity to identify potential prognostic and/or
predictive biomarkers of therapeutic response that may
facilitate the stratification of patients with responder
versus non-responder signatures.
Samples and clinical data
Two hundred six DNA copy number profiles for pediatrics
sarcoma were collected from the publicly accessible data-
bases, NCBI - Gene Expression Omnibus (GEO) [https://
www.ncbi.nlm.nih.gov/sites/GDSbrowser/] and Therapeut-
ically Applicable Research to Generate Effective Treatments
(TARGET) [https://ocg.cancer.gov/programs/target]. These
data sets included CNVs from OS (n = 117), RMS (n = 64),
and ESFTs (n = 25) (Table 1, Additional file 2). Database of
Genomic Variants (DGV) [20] specifically, the hg38 DGV
provided comprehensive genomic structure variation of
healthy individuals for the sarcoma CNV comparison.
CNVs of all sarcoma tumors were tested prior toTable 1 Datasets and their source for healthy and pediatric sarcoma
Data Type Source Plat
Healthy Individuals DGV (Database of Genomic Variants) [13] BAC
SNP
Osteosarcoma (OS) GEO (GSE33383)
TARGET
Affy
6.0
Rhabdomyosarcoma (RMS) GEO (GSE24715) Affy
Affy
Ewing Sarcoma (ESFTs) GEO (GSE8398) Agilsurgery without prior chemotherapy. The median age at
diagnosis was 15 years (range 2–20 years). These sarcomas
were intermediate to high grade (93%). The detailed clin-
ical sample annotation is listed in Additional file 2.
CCLE project provides a detailed genetic characterization
of a large panel of human cancer cell lines (n = 947) which
includes 24 cancer types [21]. Copy number profiles of
27-sarcoma cancer cells lines previously obtained by Affy-
metrix SNP Array 6.0 were collected (see Table 2 for cell
lines). The sensitivity of drug responses were quantified
using the Area Under the Curve (AUC) for 481 candidate
cancer drugs in 27 sarcoma cell lines collected from the
Cancer Therapeutics Response Portal (CTRP v2.0) [22] and
integrated with copy number alterations from the CCLE.
Results
Comparative analysis of CNVs from OS, RMS, and ESFTs
to healthy population genomes
A comprehensive assessment of CNVs using high-resolution
array CGH (Affymetrix SNP) array was completed on OS,
RMS and ESFT sarcoma patients (Fig. 1). Genes or regions
frequently comprised of these CNVs were identified by com-
paring whole genome CNVs of a healthy population from
DGV 22,255 samples.
CNV analyses and stratification based on amplification
and/or deletion frequencies were conducted for OS,
RMS, and ESFTs (Fig. 2a-c). Hierarchy clustering ana-
lyses for delineating the pattern of genomic CNVs were
conducted to stratify sarcoma patients based on their re-
lapse and metastasis status where CNV distributions
greater than the 85% range represented amplification
(OS = 2.710, ESFTs = 0.147, RMS = 0.7) and less than the
15% range signified deletion (OS = 1.414, ESFTs = −
0.1467, RMS = − 1.213) (Fig. 2a-c). CNVs that were in
between these thresholds for each sarcoma type were
considered as having no change in CNVs.
OS (n = 117) had the most common gain (copy number
amplification) in chromosomes 8, 12, 21, and X, while the
most common loss (copy number deletion) was found
in chromosomes 2, 10, and 13 (Fig. 2 A1). Combination
of copy number amplification and deletion were ob-
served in chromosomes 1, 10 and 12 which are com-
prised of genes amplified or deleted in OS pathogenesispatients
form Sample size
Acgh, FISH, OligoACGH, PCR, Sequencing,
array and Digital array
22, 255
metrix Genome-Wide Human SNP
Array chips, GPL6801
32
85
metrix Mapping 250 K Sty2 SNP chips, GPL3720 7
metrix Human Mapping 50 K Xba240 SNP chips, GPL2005 57
ent-013282 Human Genome CGH Microarray 44B, GPL2879 25
Table 2 Sarcoma cancer cell lines
Tissue Histology Cell_line Tissue Histology Cell_line
soft_tissue Rhabdomyosarcoma A-204 bone Ewings_sarcoma RD-ES
soft_tissue Rhabdomyosarcoma Hs 729 bone Ewings_sarcoma SK-ES-1
soft_tissue Rhabdomyosarcoma KYM-1 bone Ewings_sarcoma SK-N-MC
soft_tissue Rhabdomyosarcoma RD bone Ewings_sarcoma TC-71
soft_tissue Rhabdomyosarcoma RH-30 bone Osteosarcoma 143B
soft_tissue Rhabdomyosarcoma RH-41 bone Osteosarcoma G-292
soft_tissue Rhabdomyosarcoma SJRH30 bone Osteosarcoma HOS
soft_tissue Rhabdomyosarcoma TE 441.T bone Osteosarcoma Hs 870.T
soft_tissue Rhabdomyosarcoma TE 617.T bone Osteosarcoma Hs 888.T
bone Ewings_sarcoma A-673 bone Osteosarcoma MG-63
bone Ewings_sarcoma CADO-ES1 bone Osteosarcoma SJSA-1
bone Ewings_sarcoma Hs 822.T bone Osteosarcoma T1–73
bone Ewings_sarcoma Hs 863.T bone Osteosarcoma U-2 OS
bone Ewings_sarcoma MHH-ES-1
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[5, 7, 10, 11, 23–26] (details in Additional file 3: Table S1).
Frequency analyses of CNV amplifications and deletions in
the healthy population indicated the existence of CNVs in
regions such as 1q21, 10p11, and 15q25 (Fig. 2 A1).Fig. 1 Integration of genomic CNVs to chemotherapy-response for identifi
sarcoma tumor biopsies and cell lines. a CNV patterns were detected in 20
lines (OS, RMS, and ESFTs). b The CNVs identified from sarcoma cells w
patients. c Frequent CNVs were identified by literature review from PU
to evaluate drug response associated with CNVs using a Pearson Corre
biomarkers of therapeutic response in these sarcomas. f Matching sarco
biomarkers of sensitivity and resistance to chemotherapy are obtained.
chemotherapy will be identified for further explorationESFTs (n = 25) also exhibited the presence of copy
number gains in chromosomes 1, 8, and 12 (Fig. 2 B1).
Deletions (copy number loss) were found in chromo-
somes 10, 11, and X (Fig. 2 B1). Smaller aberrations
were found at chromosome regions: 11q24, 22q12, 5p,cation of predictive biomarkers of therapeutic response in pediatric
6 sarcoma (OS, RMS, and ESFTs) patients as well as in 27 sarcoma cell
ere also compared with the profile observed in the 206 sarcoma
BMED and compared with 206 patients CNVs. d,e Large screening
lation calculation was completed to identify potential predictive
ma patients CNVs to sarcoma cells. g, h, i Significant predictive
Significant predictive biomarkers of sensitivity and resistance to
Fig. 2 (See legend on next page.)
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Fig. 2 Detection of CNVs by aCGH in 206 patient tumor biopsies from pediatric sarcomas (OS, RMS, and ESFTs). (a1) Frequency plots of genome
CNV. Band frequencies (CNV deletion and amplification) in OS (horizontal axis, from 0 to 100%) are plotted as a function of chromosome location
(from 1pter to the top, to 22qter to the bottom) and compared with the healthy population (DGV). Horizontal lines indicate chromosome boundaries.
Positive and negative values indicate frequencies of tumors showing copy number increase and decrease, respectively, with amplifications of copy
number (in red) and deletions of copy number (in blue). (a2) Unsupervised hierarchical clustering of genome CNVs measured for OS on whole
genome with largest gain/lost standard variation. Red indicates increased DNA copy number (CNV gain/amplification) and blue indicates decreased
DNA copy number (CNV loss/deletion). Below the dendrogram, each column represents a clinical sample; the status of sample collection is denoted in
shades of green (see key at bottom of heat map for Relapse/Dead, Non-relapse/Alive, and Relapse/Alive); each row indicates genes and associated
chromosomes. (b1) Band frequency plots CNVs (deletion and amplification) among ESFTs compared with healthy individuals. (b2) CNVs for ESFT
patients were analyzed as described in A2. Below the dendrogram, color at top of each column indicates the diagnosis of the clinical samples
(localized disease, metastasis, or non-metastatic). Each row indicates genes and associated chromosome. (c1) Band frequency plots of the healthy
individuals and RMS patients were analyzed as described in A2. (c2) CNVs for RMS patients were analyzed as described in A2
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rent ESFT included EZH2, MYC, ATF1, IGF1, MAPK1,
FGFR1 and STAG2 (Fig. 2 B2) [2, 4, 6, 9, 27–29].
In RMS (n = 64), amplifications (copy number gains)
were found in chromosomes 2, 8, 12, and 20. (Fig. 2 C1).
Whereas, recurrent loss of heterozygosity (LOH) of
chromosomes 1, 7, 14, and X was detected (Fig.2 C1).
Genes of interest in RMS that were amplified or deleted
and may contribute to the disease pathogenesis/progres-
sion included NOTCH2, PRKCD, MYC, IGF2, MDM2
and ITGAM (Fig. 2 C2) [3, 17, 18, 30, 31]. The details
are shown in Additional file 3: Table S3.
There are 5417 overlapping genes among OS, ESFTs
and RMS at the whole genome level compared to nor-
mal healthy controls (Fig. 3). The loss of heterozygosity
(LOH) of chromosomes 1, 7, 14, and X was detected in
OS, ESFTs and RMS respectively (Additional file 4). A
common pattern of copy number gains in chromosome
8 and 12 was found in OS, RMS and ESFT. The specific
segment that was amplified in chromosome band 8q23-q24
included MYC, PMP1, ODF1, TRPS1, RAD21, SQLE,
FAM49B and LRRC6. Moreover, MYC, which is located in
8q24.21, showed the highest amplification frequency of
0.78 in OS, 0.69 in ESFTs, and was not amplified in RMS
with a frequency of 0.32. However, the pattern of CNV
exhibited differences among OS, RMS and ES on chromo-
some 1. The gene SELL had increased copy number ampli-
fications in OS compared to ESFT and RMS. Transcription
factor genes on chromosome 1 such as NOTCH2 (dele-
tion), PRKAB2 (amplification) and SELL (amplification)
also shared similar copy number alterations in all three
types of sarcomas (Figs. 3 and 4).
Significant CNVs associated with prognostic biomarkers
of pediatric sarcomas (OS, RMS, ESFTs)
Based on extensive literature review of all three sarcomas
[2–22], [https://www.ncbi.nlm.nih.gov/sites/GDSbrowser/],
[23–37], functional outcome of the most frequent CNVs
associated with poor outcome was compiled. These gene
sets for each sarcoma type is listed in Additional file 3. The
top 63 frequently amplified or deleted genes in OS, RMSand ESFTs were previously shown to be associated with
recurrent in OS, RMS and ESFTs and are shown in
Table 3. All of genes were annotated and mapped to
chromosome level by Hg19. See methods section for de-
tails on data analysis [38, 39], [http://www.affymetrix.com/
support/technical/byproduct.affx?product=500k], [40, 41].
In addition, druggable targets denoted in DrugBank
(https://www.drugbank.ca/) are included.
Comparison of CNVs between patient sarcoma tumors
and sarcoma cell lines
As described above, 63 genes that serve as potential
prognostic biomarkers were extracted from bone and
soft tissue sarcoma cell lines described in the CCLE
where CNVs were categorized based on their high fre-
quencies of amplifications and deletions (Table 2). A
hierarchy clustering was used to identify cluster patterns
across bone and soft tissue sarcoma cell lines (Fig. 5, left
panel). Associated CNV amplification frequencies in sar-
coma patient samples were compared with sarcoma cell
lines (Fig. 5, right panel). EGFR amplification was
showed to be amplified in 25% of the patient samples
and in 24% of the sarcoma cell lines. However, MYC was
amplified in 60% of the OS and ESFT patient samples
while but it was only amplified in 8% of the sarcoma cell
lines. IGF1R was amplified more frequencely in OS pa-
tients 31.3% than in RMS 13% and ESFT 12.5%.
Linking CNV profiles in pediatric sarcoma samples to
drug sensitivity in sarcoma cell lines with similar CNV
profiles
To elucidate if the CNVs identified in pediatric sarcomas,
it could be used to guide selection of therapies that will
improve clinical outcome. We next investigated the extent
of drug sensitvity in the sarcoma cell lines based on CNVs
(CCLE, Table 2). Drug sensitivity correlated with amplifi-
cations and/or deletions frequently found in the pool of
63 genes harboring CNVs (Table 2). The database CTRP
provides drug-response data of sarcoma cells. Therefore,
evaluation and comparison of drug-response with the
identified CNVs was integrated from the cell line CCLE
Fig. 3 Systematic comparison of CNVs in OS, RMS and ESFT in 206 patient tumor biopsies and 27 sarcoma cell lines. Mark as id = sample name;
id-1 = sarcoma type; id-1-2, C = cell line, T = tumor sample. Note: Unknown items in “id” denote sarcoma samples whose exact diagnosis/status at
the time of the analysis was not known
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ation analysis between CCLE and CTRP indicated that 33
CNVs from 27 sarcoma cell lines had a positive and/or
negative correlation with drug response to 17 DNA dam-
aging agents (Fig. 6). For example, IGF1R copy number
amplification correlated with sensitivity to clofarabine
(Fig. 6a, see left panel), and therefore, may serve as a “sen-
sitive” biomarker of therapeutic response to clofarabine.
Since lower concentrations of drug were needed to inhibit
growth of the sarcoma cell lines with IGFR1 copy number
amplications [see right panel that compares AUC of clo-
farabine in cell lines with IGF1R gene deletion (clofarabinenonsensitive) or amplification (clofarabine sensitive)]. The
significant correlation between clofarabine response asso-
ciated with CNVs in 27 sarcoma cell lines is illustrated in
Fig. 6b. Overall, a number of therapeutic predictive bio-
markers were found (Fig. 6c). Integration of 33 CNVs with
drug response data in sarcoma cell lines uncovered differ-
ential sensitivities to commonly used chemotherapeutic
drugs.
Discussion
Pediatric sarcomas encompass a rare group of heteroge-
neous neoplasms that arise in bone and soft tissues in
Fig. 4 Comparison of CNVs in chromosomes 1 and 8 in OS, RMS, and ESFT patient tumors. a CNVs present on chromosome 1 among pediatric
sarcomas (OS, RMS, and ESFTs). b Variation of amplification and deletion frequencies across different band regions in chromosome 8. Several
genes associated with sarcoma progression are highlighted in green. Red denotes the amplification frequency while blue represents the
deletion frequency
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ing pediatric sarcomas, clinical outcomes for these patients
still remains relatively poor due to onset of relapse/recur-
rence initiated by various molecular alterations [8–10].
While certain pediatric sarcomas like RMS and ESFTs are
more genetically defined by having chromosomal transloca-
tions, other pediatric sarcomas such as OS are considered
to be more genetically complex in nature [23–26]. For
instance, ESFTs are genetically characterized by specific
chromosomal translocations t(11;22) (q24;q12) in 85% of
ESFTs [28]. However, the remaining 15% of ESFTs haveother chromosomal translocations, which involve other
members of the FET and ETS family [9]. Similarly, alveolar
rhabdomyosarcoma is characterized by a chromosomal
translocation t(2;13) (q35;q14) or t(1;13)(p36;q14) fusing
the PAX3 or PAX7 with FOXO1 [17, 18]. On the contrary,
in sporadic osteosarcoma there are various genetic alter-
ations such as aberrations on chromosomes 15q and 8p
where inconsistent rearrangements and copy number alter-
ation have been observed [35–37].
Regardless of their genetic landscape, efforts by several
multi-institutional groups have been on-going to investigate
Table 3 CNVs (amplifications and/or deletions) frequently found in the 63 genes that serve as prognostic biomarkers for pediatric
sarcomas (OS, RMS, and ESFTS)
OS frequency RMS frequency ESFT frequency Sarcoma types (Yes = 1)
NO Band Gene Amp Del Amp Del Amp Del OS RMS ESFT
1 7p11.2 EGFRa 0.250 0.094 0.087 0.109 0.438 0.000 1 1 1
2 12q13.3 GLI1 0.156 0.375 0.891 0.000 0.313 0.188 1 1
3 2q36.1 PAX3 0.063 0.531 0.413 0.000 0.250 0.063 1 1
4 7q36.1 EZH2a 0.344 0.094 0.413 0.000 0.313 0.125 1 1
5 8q24.21 MYC 0.781 0.031 0.043 0.326 0.625 0.000 1 1
6 8q24.22 LRRC6 0.625 0.031 0.391 0.043 0.625 0.063 1 1
7 8q24.13 MTSS1 0.625 0.063 0.283 0.000 0.438 0.000 1 1
8 15q11.2 MKRN3 0.219 0.188 0.065 0.109 0.438 0.125 1 1
9 11q24.2 ST3GAL4 0.156 0.281 0.174 0.130 0.438 0.125 1 1
10 15q22.2 TPM1 0.094 0.156 0.000 0.261 0.125 0.063 1 1
11 11q23.1 IL18 0.063 0.375 0.043 0.283 0.000 0.500 1 1
12 11p15.4 TRIM21 0.063 0.500 0.174 0.109 0.000 0.563 1 1
13 10q23.31 ACTA2 0.000 0.906 0.087 0.326 0.125 0.375 1 1
14 8q22.3 ODF1 0.875 0.031 0.413 0.087 0.688 0.188 1
15 8q24.13 SQLE 0.875 0.031 0.696 0.022 0.938 0.063 1
16 8q24.11 RAD21 0.781 0.031 0.304 0.022 0.625 0.063 1
17 8q23.3 TRPS1 0.656 0.063 0.283 0.000 0.500 0.063 1
18 8q21.13 PMP2 0.594 0.094 0.913 0.000 0.125 0.375 1
19 8q24.13 TMEM65 0.531 0.063 0.217 0.087 0.500 0.188 1
20 1q24.2 SELL 0.688 0.063 0.674 0.000 0.188 0.125 1
21 15q26.3 SNRPA1 0.688 0.125 0.000 1.000 0.125 0.188 1
22 22q11.21 MAPK1a 0.406 0.219 0.000 0.587 0.000 0.688 1
23 15q26.3 IGF1R 0.313 0.094 0.130 0.065 0.125 0.000 1
24 15q26.1 KIF7 0.563 0.063 0.065 0.435 0.375 0.000 1
25 12p13.31 CD163 0.500 0.063 0.174 0.152 0.125 0.125 1
26 16p13.3 MAPK8IP3 0.000 0.813 0.630 0.043 0.688 0.000 1
27 10q22.1 NUDT13 0.000 0.781 0.739 0.000 0.125 0.438 1
28 10q22.1 P4HA1 0.000 0.688 0.935 0.000 0.125 0.313 1
29 10q23.1 TSPAN14 0.000 0.688 0.043 0.413 0.000 0.750 1
30 11q13.1 CFL1 0.406 0.125 1.000 0.000 0.063 0.313 1
31 9q22.33 ALG2 0.625 0.031 1.000 0.000 0.500 0.000 1
32 1q21.1 PRKAB2 0.406 0.063 1.000 0.000 0.313 0.188 1
33 16p11.2 ITGAL 0.063 0.375 0.978 0.000 0.375 0.250 1
34 7q21.2 PEX1 0.438 0.094 0.978 0.022 0.063 0.438 1
35 3p21.1 PRKCDa 0.125 0.156 0.978 0.000 0.063 0.250 1
36 12q21.1 THAP2 0.344 0.219 0.978 0.000 0.438 0.063 1
37 19q13.33 AP2A1 0.125 0.063 0.935 0.000 0.063 0.375 1
38 16p11.2 ITGAM 0.031 0.406 0.913 0.000 0.063 0.250 1
39 10p14 KIN 0.031 0.563 0.913 0.000 0.125 0.375 1
41 12q15 MDM2 0.156 0.187 0.391 0.130 0.125 0.500 1
40 11p15.5 IGF2a 0.1875 0.1875 0.283 0.0217 0.75 0 1
42 11q25 B3GAT1 0.063 0.125 0.000 1.000 0.813 0.000 1
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Table 3 CNVs (amplifications and/or deletions) frequently found in the 63 genes that serve as prognostic biomarkers for pediatric
sarcomas (OS, RMS, and ESFTS) (Continued)
OS frequency RMS frequency ESFT frequency Sarcoma types (Yes = 1)
NO Band Gene Amp Del Amp Del Amp Del OS RMS ESFT
43 11q13.1 PYGM 0.563 0.063 0.000 1.000 0.313 0.063 1
44 11q13.1 RELA 0.031 0.688 0.000 1.000 0.625 0.063 1
45 3p14.1 PSMD6 0.125 0.656 0.000 1.000 0.250 0.000 1
46 1p12 NOTCH2 0.500 0.000 0.000 1.000 0.375 0.125 1
47 12p13.2 ETV6 0.156 0.156 0.239 0.000 0.750 0.000 1
48 5q32 PDGFRBa 0.063 0.531 0.065 0.870 0.750 0.000 1
49 7p12.3 IGFBP3 0.156 0.188 0.065 0.000 0.688 0.000 1
50 7p21.2 ETV1 0.156 0.063 0.152 0.000 0.563 0.000 1
51 7q33 CREB3L2 0.281 0.094 0.087 0.152 0.125 0.000 1
52 17q21.31 ETV4 0.094 0.250 0.196 0.196 0.563 0.063 1
53 10p11.21 ANKRD30A 0.094 0.438 0.196 0.000 0.500 0.125 1
54 4q12 KITa 0.219 0.063 0.000 0.130 0.375 0.000 1
55 12q23.2 IGF1a 0.125 0.094 0.130 0.043 0.250 0.000 1
56 21q22.2 ERG 0.469 0.063 0.109 0.022 0.188 0.063 1
57 20q13.2 NFATC2 0.313 0.219 0.000 0.326 0.188 0.063 1
58 11q24.3 FLI1 0.156 0.125 0.043 0.348 0.188 0.125 1
59 xq25 STAG2 0.031 0.813 0.326 0.022 0.125 0.750 1
60 xp11.4 BCOR 0.000 0.938 0.130 0.217 0.438 0.563 1
61 17q12 TAF15 0.188 0.313 0.370 0.022 0.125 0.500 1
62 6p22.3 KIAA0319 0.375 0.031 0.022 0.391 0.063 0.500 1
63 12q13.12 ATF1 0.281 0.125 0.000 0.326 0.313 0.438 1
Note: adenotes gene with druggable targets by DrugBank annotation. Designation of “1” indicates there is literature to support that specific gene is deleted or
amplified for that sarcoma type. All frequency calculation is based on 206 sarcoma patients CNVs
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these pediatric malignancies. However, even with these ad-
vancements, the 5-year survival rates for relapsed/recurrent
pediatric sarcoma patients still remain less than 30% [1, 2].
Therefore, along with identifying downstream targets of
these molecularly-characterized and complex pediatric sar-
comas, it is equally imperative to assess and identify other
acquired genetic changes such as CNVs involving genetic
amplifications and/or deletions that may provide novel
therapeutic options to improve clinical outcomes [29]. Not-
ably, OS, RMS, and ESFT exhibit various CNVs that can
serve as prognostic biomarkers for these pediatric sarcomas
[23–31]. Our objective for this study was to identify CNVs
common to all three of the pediatric sarcomas (OS, RMS,
ESFTs) and evaluate the role of these CNVs in response to
DNA damaging agents to determine if they are predictive
biomarkers of therapeutic response. This comprehensive
study investigated band and gene alterations of somatic
copy number amplification and deletion in 27 bone and
soft tissue sarcoma using aCGH arrays (Affymetrix).
Due to increased availability of publicly available data-
sets, improved and efficient resources for integrative
genomic sequencing, and molecular characterization ofpatient-specific tumors it is now feasible and could be po-
tentially used to guide selection of personalized therapies.
Through our comparative genomic analyses of OS,
RMS, and ESFTs and healthy subjects, we identified CNVs
(amplifications and deletions) in various chromosomal
regions (Fig. 2). Bioinformatics analyses was also con-
ducted to identify the pattern of genomic instability in
these pediatric sarcomas. To the best of our knowledge,
this is the first study to compare genomic instabilities
between OS, RMS, ESFTs and healthy population con-
trols. Genes associated with survival and/ recurrence of
these sarcomas with statistical significance were found on
long arm of chromosome 8 with much higher amplifica-
tion frequency observed in OS (0.8–0.92). These include
MYC (8q24.21), LRRC6 (8q24.22), MTSS1 (8q24.13),
ODF1 (8q22.3), SQLE (8q24.13), RAD21 (8q24.11), TRPS1
(8q23.2), PMP2 (8q21.13), TMEM65 (8424.13). In ESFTs,
there is higher amplification frequency (0.5–0.7) for
majority of the bands and lower deletion frequency (0–
0.1) in chromosome 8. Similar results are obtained in
RMS. CNVs, in particular, amplifications involving
chromosome 8 have also been reported by other groups
in OS, RMS, and ESFTs, thus, further validating our
Fig. 5 Comparison of CNVs between sarcoma patients and sarcoma cell lines. The left panel represents the CNVs on 27 sarcoma cells, where
green is type of bone sarcoma and brown is type of soft tissue sarcoma. The right panel represents the amplification or the deletion frequency of
copy number variation in sarcoma patients, which is associated with CNVs of the sarcoma cells
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assess the role and function of many of the amplified
genes present on chromosome 8 in pediatric sarcomas,
one key gene that has been highly studied in these
pediatric sarcomas is MYC, which has a role in various
other cancers [36, 37]. MYC is a transcription factor
that is known to regulate critical biological functions
such as cell cycle, apoptosis, and metabolism [36]. Gen-
etic alterations that result in changes to MYC, such as
MYC amplification, can dysregulate its normal functionand alter the balance between being a tumor suppressor
versus being tumorigenic [36]. Along with chromo-
somal changes observed in chromosome 8, smaller ab-
errations in OS, RMS, and ESFTs were also identified at
chromosomes 1q, 12q and x. The long arm (1q) of
chromosome 1 also signifies amplification with gene
SELL showing higher significance in OS. The majority
of the bands in the long arm (1q) of chromosome 1
have an amplification frequency 0.2–0.4 while the dele-
tion frequency is between 0.1–0.2 in ES. Several CNV
Fig. 6 (See legend on next page.)
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Fig. 6 CNVs as predictive biomarker for chemotherapy in pediatric sarcoma. Gene IGF1R and clofarabine response provide an example of data
integration. IGF1R gene amplification correlates with increasing sensitivity to clofarabine in pediatric sarcoma. a Correlation of IGF1R CNV and relative
sensitivity to clofarabine. The IGF1R CNV status (deletion or amplification) for each cell line is presented in the middle of the panel (Del = gene deletion
denoted in green; Amp= gene amplification denoted in red). The y axis signifies the response of each cell line to clofarabine and is presented as the
area under the curve (AUC) to drug response. Blue circles = cell lines with IGF1R deletion; Red circles = cell lines with IGF1R amplification (left panel);
Drug response data compiled as non-sensitive (NS) versus sensitive (S) cell lines,*p < 0.01, IGF1R deletion vs. IGF1R amplification, right panel b Strong
linear correlation between IGF1R CNV and clofarabine response. Blue circles = cellular response to clofarabine; y-axis = AUC and x-axis = CNV of IGF1R.
(c) CNVs as chemotherapy biomarkers in sarcoma. The sensitive and non-sensitive biomarker selection is based on the threshold where a threshold of
p < 0.05 and correlation coefficient r > 0.35 denotes non-sensitivity and r < − 0.35 signifies sensitivity
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accuracy of our results.
However, CNVs associated with recurrence in these
pediatric sarcomas correlate with poor prognosis by specific
chromosomal translocations or variations in OS, RMS, and
ESFTs that can serve as prognostic biomarkers for these
diseases [4–7]. To date, the correlation between these prog-
nostic biomarkers and their response to therapies still re-
quires further exploration using in vivo pediatric sarcoma
models.
We identified CNVs in 63 genes among the three
pediatric sarcomas (OS, RMS, and ESFTs) that correlated
with the recurrence of the diseases, suggesting CNVs in the
63 genes may provide prognostic biomarkers for these sar-
comas. The 63 genes have high frequency of amplifications
as well as deletions in these sarcomas. For example, genes
such as KIF7, IGF1R and SNRPA1 on 15q16.1-15q16.4 are
amplified in OS. In RMS amplification of PAX3 (2q36.1)
with frequency of 0.413 was observed, whereas, a high dele-
tion frequency of 0.9–1 was evident in CFL1, ALG2,
PRKAB2, ITGAL, PEX1, PRKCD, AP2A1, KIN, ITGAM,
THAP2 genes. ESFTs exhibit frequently mutated STAG2
on chromosome Xq25 [2, 40] with a high deletion fre-
quency of 0.75 in our study.
By integrating large-scale drug screening to evaluate
drug response profiles of the CNVs identified in 63
genes from 27 sarcoma cell lines it was identified that 33
genes with CNVs had either sensitive or non-sensitive
responses to 17 chemotherapies. The CNVs in these 33
genes could serve as potential predictive biomarkers of
therapeutic response which still needs to be further ex-
plored. An example of this included the CNVs identified
in IGFR1 (Table 3). IGFR1 is receptor for the growth
hormone insulin growth factor (IGF) which can mediate
cell proliferation [26]. Binding of IGF to IGFR1 initiates
downstream singling cascades to increase cell proliferation
and decrease apoptosis, which is observed in these pediatric
sarcomas [26]. Figure 6a, b show that CNVs in IGFR1 result
in IGFR1 serving as a sensitive biomarker of therapeutic
response to Clofarabine. Clofarabine is a purine nucleoside
analog that can inhibit DNA/RNA polymerases and pro-
motes apoptosis of cancer cells [41, 42]. This study provides
novel insights into how genetic alterations such as CNVs
can potentially serve as both prognostic biomarkers andpredictive biomarkers of therapeutic response in pediatric
sarcomas. The systems pharmacology approach described
here provides a platform to personalize therapies that have
could improve clinical outcomes in aggressive pediatric ma-
lignancies [43, 44].
Conclusions
In our study, we evaluated CNVs as well as their frequen-
cies of amplification (copy number gain) and deletion
(copy number loss) in a large cohort of OS, ESFTs, and
RMS patient samples and sarcoma cell lines. To the best
of our knowledge, this is the first study screening
genomic-profiling (CNVs) of aggressive pediatric sarco-
mas and assessing their drug-responses to potentially
improve therapeutic and clinical outcomes in these
aggressive diseases. Our future studies will be focused
on functionally validating identified targets using in vivo
modeling approaches and evaluating their roles as a poten-
tial predictive and/or prognostic biomarker in our quest to
improve the currently dismal therapeutic outcomes in
pediatric sarcoma patients.
Methods
Data collection
Healthy subjects
The comprehensive genomic structure variation data for
the healthy individuals was collected from the Database
of Genomic Variants [20]. Fifty-five published studies
were included in DGV, from the well-known archival SV
databases including, dbVar (NCBI) and DGVa (EBI). The
latest dataset GRCh 37 (hg19) version released on May
15, 2016 is collected [45]. A total of 488,630 variant
records in 22,255 samples were used to study the CNVs
representing a total of 14,316 non-redundant individuals
across ~ 44 different populations representing both
males and females almost equally. Each of these entities
contain multiple studies from different analysis. Insertion,
deletion, duplication, tandem duplication, novel sequence
insertion and mobile element insertion in chromosomes
were investigated. All genomic variants in DGV were de-
tected by different experiment methods, including Bacterial
Artificial Chromosome (BAC) and oligonucleotide-based
chromosomal Comparative Genomic Hybridization (Oli-
go-cCGH), aCGH, fluorescence in situ hybridization (FISH),
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nucleotide polymorphism (SNP) array and Digital array.
The latest data consists of 44% from microarray studies,
33% from sequencing and 3% from FISH/PCR and Optimal
Mapping. The size of the DNA segment for CNV ranges
from 50 bp to 3Mb, with lesser number of variants in the
range of 50 bp to 1 Kb range. This is because the majority
of the CNV detected using microarray is large-scale CNV.
All genome region segments of CNVs were obtained and
mapped to genes and bands for further study.
OS
One hundred seventeen OS are collected from TARGET
and GEO database respectively, where both data sets
were tested by Affymetrix Genome-Wide Human SNP
6.0 Array chips (GEO platform accession ID, GPL6801).
85 samples from TARGET [12] were obtained and seg-
ments of CNVs with level 3 data were selected. 32 CEL
files of CNV profile were obtained from GEO accession
ID, GSE33383 with high-grade OSs. Both datasets pro-
vide clinical information about each subject including
recruitment, demographics, survival and physical exami-
nations (Table 4).
ESFTs
CGH profiling of 25 ESFT tumor samples, from GEO ac-
cession ID, GSE8398 (65), were scanned on Agilent-013282
Human Genome CGH Microarray 44B (GEO platform ac-
cession ID, GPL2879). All 25 sample CEL files were usedTable 4 Demographics and clinical characteristics of sarcoma patien
Sarcoma Type Data Source
OS TARGET Stage1
Stage2
Gender
Vital Status
Age
High Grade OS GEO-GSE33383 Age
ESFTs GEO-GSE8398 Gender
Stage
RMS GEO-GSE24715 Histology Subtypefor data analysis. The datasets provided detailed clinical in-
formation of samples, such as disease stage, site of disease,
occurrence of metastasis and patient status (Table 4).
RMS
CGH profilings of 64 alveolar RMS genome variation,
from GEO accession ID, GSE24715. 7 sample genome
variation was tested by Affymetrix Mapping 250 K Sty2
SNP chips (GPL3720 in GEO, 238378 probe sets), while
57 samples were tested on Affymetrix Human Mapping
50 K Xba240 SNP Array (GEO platform ID: GPL2005).
The raw CEL files were used to generate the CNVs,
which were further analyzed for deletion and amplifica-
tion frequencies.
Cancer cell line encyclopedia
All segments of copy number variations for 27 sarcoma
cell lines were collected from CCLE, which were tested
by Affymetrix Genome-Wide Human SNP Array 6.0.
Log 2 transformed segment values were used for further
analysis.
Data pre-processing and gene annotation
All CEL files obtained from GEO were quantified using
the Bioconductor package in R. The Oligo library was
used to obtain the copy number values for the DNA seg-
ments by MAS 5.0 algorithm. The normalized log2 ratio
(healthy/tumor) on probe-sets was annotated to genes
for further analysis. All continuous variable CNV will bets
Clinical Information Number of Samples
Relapse 41
Non-Relapse 44
Metastatic 22
Non-Metastatic 63
Female 37
Male 48
Alive 55
Dead 30
At the time of Diagnosis (days):
1299–11,828
85
At the time of Diagnosis (days):
3072–14,965
32
Female 11
Male 9
Unknown 5
Metastatic 11
Localized 9
Unknown 5
ARMS (Alveolar rhabdomyosarcoma) 64
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letion, − 1 is deletion, 0 is no change of CNV, 1 is ampli-
fication and 2 is significant amplification. Base on whole
CNV histogram distribution of a particular array plat-
form, the CNV value is larger than top 5% range, we set
CNV as 2; when the CNV is large than 15% range and
less than top 5% range, it sets as 1. The CNV value is
less than negative 5% range; we set CNV as − 2. The
CNV value is less than negative 15% range and larger
than negative 5% range, it sets − 1, others sets 0.
The HGNC (HUGO Gene Nomenclature Committee,
http://www.genenames.org/) database provides researchers
with standard gene names for the human genome to avoid
the complexity of multiple overlapping and conflicting
nomenclature systems. The database currently consists of
around 24,000 genes and their corresponding approved gene
symbols. Each gene has a unique HGNC ID which makes it
easier to identify the gene type. Genes were also annotated
with other information including gene synonyms, uniprot
ids, refseq ids, previous gene symbols and a functional de-
scription about each gene, all of which aids in integrating
the information from the NCBI or other databases [46].
By software Bedtools ‘intersectBed’, we mapped genome
region segments of CNV to gene symbols by GRCh37/
hg19 genome annotation file [38]. All segment data re-
cords were changed into individual genes and associated
bands on chromosomes. For this work, all the genes were
mapped to their standard HGNC name using the annota-
tions from Ensemble-Biomart [45] for multi-data integra-
tion and comparison.High-resolution array comparative genomic hybridization
(aCGH) Chip and Assay
(1) Affymetrix Genome-Wide Human SNP 6.0 Array
(GPL6801) contains 934,946 SNPs and 946,371
non-polymorphic probes for the detection of CNVs.
Enzymes Nsp I and Sty I were used in parallel in
the assay to digest and fragment DNA. Probes on
the SNP Array 6.0 are targeting sequences that may
sit on fragments cut by either enzymes or both. All
SNP probes occur in a Nsp, Sty or Nsp + Sty
fragment, but the CN probes occur only Nsp and
Nsp + Sty fragments (not Sty-alone fragments). The
total genomic DNA (500 ng) was digested with Nsp
I and Sty I restriction enzymes into fragments and
ligated to adaptors that recognize the cohesive 4 bp
overhangs. A generic primer that recognizes the
adaptor sequence was used to amplify adaptor-
ligated DNA fragments. The amplified DNA is then
labeled and hybridized to a SNP Array 6.0. PCR
conditions will be optimized to preferentially
amplify fragments in the 200 to 1100 bp size range.The Birdsuite software is applied here to identify rare
CNVs from the Affymetrix SNP 6.0 array via a one-
dimensional Gaussian mixture model (GMM) [39].
We matched 946,371 CNV probes to 22,891 genes by
GEO released platform GPL6801 annotation.
(2) The GeneChip® Human Mapping 500 K Array is
one of the aCGH chips designed by Affymetrix
Company. It is comprised of two arrays, each
capable of genotyping on average 250,000 SNPs
(approximately 262,000 for Nsp arrays
corresponding to CNV and 238,000 for Sty arrays
associated with SNPs. GPL3720 in GEO is a
platform of Affymetrix Mapping 250 K Sty2 SNP
Array, which is a subset of the GeneChip® Human
Mapping 500 K Array Set. The array has probes for
CNVs and each marker can be interrogated with
up to five probes, ensuring cross-verification for
data integrity [http://www.affymetrix.com/support/
technical/byproduct.affx?product=500k].
Affymetrix Human Mapping 50 K Xba240 SNP
Array is the GeneChip® Mapping 100 K Set for
SNPs (GPL2005). It is comprised of a set of two
arrays that enable genotyping of greater than
100,000 SNPs with a single primer. All CEL files
are normalized to digital number by Affymatrix NET
‘cdf ’ package in R [http://www.affymetrix.com/
support/technical/byproduct.affx?product=500k].
(3) Agilent-013282 Human Genome CGH Microarray
44B (GPL2879) is a high performance 60-mer
oligonucleotide, allowing genome-wide survey and
molecular profiling of DNA copy number changes
on a single chip. It consists of 44,290 60-mer
oligonucleotide probes, 7321 genes, empirically
validated in multiple model systems, spanning
coding and noncoding sequences with average
spatial resolution of 35 kb.
Copy number amplification and deletion frequency
calculation based on gene or band
Copy number alterations were derived from aCGH chips
and measured using log2 ratios of the fluorescence in-
tensities from two channels (Cy3 and Cy5), one for the
target sample and the other for the reference sample.
For a given gene (or region), a negative log2 ratio is an
indication of a loss, and a positive log2 ratio is an indica-
tion of a gain. If the log2 ratio equals zero, the target
sample and the reference sample have the same copy
number for that given gene (or region). However, it
should be noted that different platforms can demon-
strate differences in amplifications and deletions even
when using the same strategy to normalize data from
CEL file to digital number. To compensate for this vari-
ability in platforms, we used equal quartiles for integra-
tion of all pertinent datasets.
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were based on the quantile distribution for any gene set,
the extreme values present in lower threshold (less than
15% range, such as <= − 0.146768) and in upper thresh-
old (more than 85% range, such as > = 0.147642) are
considered as significant threshold for deletion and ampli-
fication respectively. Similarly, for the band, the extreme
values present in lower quartile (less than 15% range,
<= − 0.16109) and in upper quartile (more than 85%
range, > = 1.7007) are considered as significant for de-
letion and amplification respectively.
For each of the genes, the total number of samples
studied, total number of observed gains in those set of
samples and total number of observed loss in the same
set of samples is calculated. The amplification fraction
and deletion fraction for each of the genes is then calcu-
lated using the formula below:
(i). Deletion frequency for each gene = Total number of
observed losses for a specific gene/Total number of
samples for that gene.
(ii). Amplification frequency for each gene = Total
number of observed gains for a specific gene/Total
number of samples for that gene.
To study the amplification and deletion fraction for a
unique band similar steps are applied as for these genes.
The total number of genes is calculated in each band to a
given chromosome. The amplification and deletion frac-
tion for these bands is calculated using the formula below:
(i) Deletion frequency for each band = Total number of
observed losses for a band/Total number of samples
for a specific gene × Total number of genes for that
specific band.
(ii) Amplification frequency for a band = Total number
of observed gains for a band/Total number of
samples for a specific gene × Total number of genes
for that specific band.
Large scale of drug screening
Cancer Therapeutics Response Portal (CTRP v2.0) pro-
vides more than 481 small molecules screening on 664
cancer cell lines [22]. Twenty-seven sarcoma cancer cell
lines were included from CTRP. Pharmacologic area
under the dose-response curve test AUC is used to de-
scribe the drug response reaction. Drug efficacy estima-
tion of AUC values, a nonparametric spline regression
technique with the constraint that each drug’s higher
dose concentration provides at least equal or higher
drug efficacy (inhibition) than its lower concentration
was applied for estimating the drug activities across each
drug’s experimental range of dose concentration. The
successive parabolic interpolation for one-dimensionaloptimization, implemented with the nlminb routine of
R, was used to obtain the final AUC estimates by invert-
ing the dose-effect curves.
Statistical analysis
All code and programming were done using R. Pearson cor-
relation coefficient is used to calculate association between
drug response AUC and copy number variation in each of
gene. GENE-E software (https://software.broadinstitute.org/
GENE-E/) is used for clustering analysis and visualization.
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